RNAi screening in the era of high-throughput genetics
0
SHARES
Posted: 12 December 2009 | Steven Haney, Associate Fellow, Pfizer | No comments yet
The use of RNAi screening to identify potential drug targets has enjoyed great success in recent years as a robust method for linking genes to a disease process through a functional assessment of a gene in an experimental model1. True, RNAi screening is complicated by problems such as off-target effects and toxicities associated with various properties of RNAi molecules, but effort from many groups has produced a coherent set of guidelines that are useful for most RNAi screens2-4. As such, large scale RNAi screens can be performed by moderately-resourced laboratories. RNAi screens have identified genes involved in resistance to anticancer chemotherapeutics, viral and bacterial infection and specific signal transduction pathways. Now that the technical complications have been identified and largely mitigated, RNAi screening has joined other genomic technologies, such as transcriptional profiling, as a method for broadly surveying the human genome for roles in a given disease or a response to a treatment.
The use of RNAi screening to identify potential drug targets has enjoyed great success in recent years as a robust method for linking genes to a disease process through a functional assessment of a gene in an experimental model1. True, RNAi screening is complicated by problems such as off-target effects and toxicities associated with various properties of RNAi molecules, but effort from many groups has produced a coherent set of guidelines that are useful for most RNAi screens2-4. As such, large scale RNAi screens can be performed by moderately-resourced laboratories. RNAi screens have identified genes involved in resistance to anticancer chemotherapeutics, viral and bacterial infection and specific signal transduction pathways. Now that the technical complications have been identified and largely mitigated, RNAi screening has joined other genomic technologies, such as transcriptional profiling, as a method for broadly surveying the human genome for roles in a given disease or a response to a treatment.
The use of RNAi screening to identify potential drug targets has enjoyed great success in recent years as a robust method for linking genes to a disease process through a functional assessment of a gene in an experimental model1. True, RNAi screening is complicated by problems such as off-target effects and toxicities associated with various properties of RNAi molecules, but effort from many groups has produced a coherent set of guidelines that are useful for most RNAi screens2-4. As such, large scale RNAi screens can be performed by moderately-resourced laboratories. RNAi screens have identified genes involved in resistance to anticancer chemotherapeutics, viral and bacterial infection and specific signal transduction pathways. Now that the technical complications have been identified and largely mitigated, RNAi screening has joined other genomic technologies, such as transcriptional profiling, as a method for broadly surveying the human genome for roles in a given disease or a response to a treatment.
Genomic technologies report on differences between states, such as normal and transformed cells or tissues, and how cells respond to a perturbation. Each technology has inherent strengths and weaknesses. Effectively using these approaches is rooted in understanding how to combine them such that the strengths of one mitigate the weaknesses in another. Transcriptional profiling reports on genes that are differentially regulated, but can not distinguish between those that cause a phenotypic change from those that result from or define the phenotypic change. Protein-protein interaction networks identify functional groups of proteins (and their cognate genes) that can be combined with transcriptional profiling data to establish network-level changes. Thus, an integrated approach to unbiased data sets can reinforce the findings of individual studies, and can enable specific molecular hypotheses to be developed and tested5. Since transcriptional profiling experiments typically hundreds, or even thousands, of genes this has been a daunting challenge. In contrast, RNAi screening is valuable for identifying genes relevant to a biological process through a functional consequence and complements methods that are agnostic to cause-or-effect differences.
More recently, human genetics has accelerated its pace as a method for identifying differences between healthy and diseased states, and by extension, differences between normal signaling pathways and those that are dysfunctional. These pathways are potentially sensitive to therapeutic intervention. Most methods have improved as a result of the human genome sequencing efforts, either in the data generated, such as high density SNP (single nucleotide polymorphism) chips, or in the methods that had been developed during the program, such as Next Generation Sequencing (NGS). SNP chips have been used to track the prevalence of common polymorphisms (generally defined as occurring in >5% of the population) in normal and disease groups. In genome-wide association (GWA) studies, SNPs showing an enrichment of one allele in one of the study groups can implicate one or more genes within the region of that SNP that may play a role in the disease. NGS can identify mutations in coding regions of genes directly.
Are you looking to explore how lipid formulations in softgels can enhance drug absorption and bioavailability. Register for our upcoming webinar to find out!
3 September 2025 | 3:00 PM BST | FREE Webinar
This webinar will delve into the different types of lipid formulations, such as solutions, suspensions, emulsions, and self-(micro)emulsifying systems. Applications span diverse therapeutic areas including HIV therapy, oncology, immunosuppressants, and emerging treatments like medicinal cannabis (eg, CBD).
What You’ll Learn:
Lipid formulation development and screening tools for optimisation
Key steps in scale-up and industrialisation to ensure consistency and efficiency
Impact of lipid-based softgels on drug delivery and patient outcomes.
The advantage of leveraging human genetic data is that the genes identified are defined by their role in human disease. In contrast, RNAi screening or transcriptionally profiling of a human cancer cell line identifies genes that are relevant to the survival of that cancer line under the conditions tested (typically as a mono-culture in atmospheric oxygen and enriched media), but translating such effects to cancer in humans requires that the model system truly recapitulate events in the tumour. Such caveats can be overstated, for example breast cancer models of Her-2NEU over-expression are effective for evaluating anti-Her-2NEU therapeutics, despite being cultured ex vivo for decades. However, an initiative will only succeed in developing a therapeutic if a concordance between a model and a disease mechanism exists. The strongest advantage to human genetic studies of disease is that this concordance is explicit. Genes or chromosomal loci are only identified as significant if they are present to different degrees between the control and the disease groups. Therefore, a gene that is identified directly (by NGS) or implicated by its locus (through SNP genotyping) affects the onset or progression of the disease under study in an authentic human population. While not directly related to the methodology, an additional advantage to SNP-based studies is that most studies identify only a limited number of genes, often less than 20 genes and frequently less than 10. In contrast, transcriptional profiling and RNAi screening typically identify many more genes, and these gene lists are known to include many that are responding to, rather than driving, the biological problem (in the case of transcriptional profiling) or to include technical artifacts (false positives in the case of RNAi screening). Larger scale sequencing methods are also generating larger lists of candidate genes, but informatics methods are developing in parallel to reduce the total number of mutations to a refined list of candidates (discussed below).
Understanding why the mutations confer sensitivity to a disease is the major challenge. If genes identified in genetic studies are (indeed) defined by the statistical significance, there is frequently little information available on why the mutation, or the gene affected by the mutation, plays such a causative role. In fact, no information can be inferred on what the relevant cell type, tissue or organ is. Additional methods are necessary to develop a mechanistic context for understanding how the mutation affects disease. Expression studies are valuable for defining a list of cell types or tissues to focus on, but even then caution is needed if the expression studies are themselves generated in cell lines or primary culture of cells taken out of their native environment. Ironically, well-characterised genes can lead to prematurely focusing on a particular cell type, when in fact, several cell types ought to be considered.
Genes identified through high-throughput genetics
An overview of recent studies in human genetics has been presented above, but it is worth taking a moment to discuss the results generated from them in more detail. Sequencing methods have focused on pre-selected genes, and so they have not been completely unbiased, but the number of genes has been increasing, and sequencing the exome (all exons) is now possible6. Mutations identified by sequencing are still evaluated for their statistical significance, based on their occurrence in a disease group and compared to the frequency of occurrence in a control group, so even though coding sequence mutations are strongly indicative of a consequential impact on disease, such mutations are not truly ‘smoking guns,’ and still require additional validation. In the case of somatic mutations found in human tumours, many mutations are identified in the tumour samples, and the oncogenic (driver) mutations need to be distinguished from other (passenger) mutations. Exon sequencing is distinct from transcriptome sequencing, in that the DNA is sequenced rather than RNA, and therefore expression information can not be derived from the mutational data.
SNP studies have grown from early work cataloging normal genetic variation in human populations, and then searching for unusual patterns (distributions) of specific variants that correlate with the occurrence of a disease or another measurable parameter. Each loci identified in such a study may implicate one or more genes. SNPs identified as most significant are compared with additional SNPs and the genes that reside in the locus. In the example shown in Figure 1, the most significant SNP identified in the figure, rs10923931, is shown as a diamond near the top of the figure. Additional SNPs are also shown, those that correlate with query SNP are shown in darker colour than those that do not. The recombination rate is shown as the blue line, chromosomal regions that lie within the recombination boundaries are associated with the query SNP, and in this example include the genes NOTCH2 and ADAM30. Those that lie across the boundary are not associated with the query SNP, such as the genes HMGC182, PGDH3 and REG4.
Genes identified in these studies include a few that are very likely to play some role in the disease in question, although it is most likely that only one gene within a locus is actually playing such a role. The challenge then becomes determining the function of the gene as it pertains to the disease. This is particularly difficult when one considers the genes that are identified in these studies. Looking as several GWA studies, the genes considered as candidates include some that can easily be fit into a mechanistic rationale while others are poorly characterised or implicate biological processes not normally associated with the disease. A couple of examples are listed in Table 1. In many cases, fundamentally novel genes are identified in addition to genes that have been well-characterised in at least one cell type. As such, some genes may present a path forward for their study, whereas others have no known function or pathway. Additionally, our understanding of the genome is still evolving, and alternative transcripts exist that are not targeted in most RNAi studies. One example is ARNIL, an expressed transcript within the CDKN2B locus. Variants that map to this locus are associated with diabetes7 and atherosclerosis8. This region includes a long transcript (designated ARNIL) in the opposite orientation to CDKN2B and spans many of the SNPs showing a correlation with these diseases. Disease-associated variants have been shown to affect expression CDKN2A, CDKN2B and ARNIL, all of which lie within this region9. Therefore, a strict interpretation of the available data is that any of the three genes within the region identified in several studies may be playing a causative role, and it is not necessarily true that the same mutation or gene is causing multiple diseases.
Lastly, while the disease-causing mutations have occasionally been identified as coding changes to the open reading frame (for example some of the MODY group of diabetes genes that include TCF7L2 and GCK), in many cases such mutations have not been identified. The mutations that cause disease are likely to alter expression levels. This is an important observation for validation studies, as it is consistent with the use of RNAi as a validation method, since it explicitly affects gene expression levels. If a common mechanism of increased disease risk is not through the altered function of the gene product, but instead is through altered expression of the gene product, the use RNAi screening to investigate the role of genes in disease is more than just a surrogate method of perturbation, it can reasonably model the authentic effect of the mutation.
Validation of novel and uncharacterised genes for roles in disease
Since a genetic mutation identifies physical region of a chromosome, and does not directly implicate a gene or even the cell type where the mutation exerts its effect, a full consideration of the candidate targets requires broadening list of genes screened, as well as the biological systems available to study these genes. Some of the factors that need to be adjusted to broaden the biological systems are diagramed in Figure 2. RNAi screening in support of GWA results is distinct from genome-scale RNAi screening in several important ways. A couple of these are a result of the differences in scale of screening for the two approaches. Screening a family of druggable targets or a larger group of genes requires standardisation of the screening assays and data analysis10. For example, the list of protein kinases approaches a thousand genes and this group is frequently screened with additional groups of druggable targets, such as the G-protein coupled receptors (GPCRs) or the nuclear hormone receptors (such as the glucacorticoid receptor). Configurations of the druggable targets gene families frequently total more than 5000 genes. Successfully screening such a library requires robust statistical methods that are appropriate for RNAi screens2,11, and follow-on methods to eliminate false positives, which are frequent in large scale screens3,4. Screening at a large scale means that several concessions are important. For example, the cells or cell lines used must be amenable to handling with automation, including sitting in reservoirs for periods of time, and must plate reproducibly. As a consequence, large scale RNAi screening requires changes in the cellular systems to accommodate screening. Most commonly, this includes immortalisation or transformation. These changes eliminate some biological questions from being addressed by large scale screening, however screens to characterise specific signaling pathways (e.g. JAK-STAT, EGFR) and some cellular processes (e.g. pathways used by infectious agents to invade a host cell) have been successful.
In contrast, screening for a causative role by an uncharacterised gene increases the necessity that the cell system used be as close to its native environment as possible. In large part, this is because a causative role may still be indirect, such as cell stress affecting glucose regulation in the liver or skeletal muscle, and such roles can not be determined a priori. This applies both to the genetic alterations in the cell system screened (an immortalised line will have lost expression of CDKN2A and CDKN2B, so these genes, as well as genes that impinge on these, will fail to show an effect in a functional test), as well as to the culture of the cells themselves. Primary cells are challenging to work with, and minor changes in their handling can cause critical cell type-specific functions to be lost. These effects have been noted by work in the toxicology and stem cell biology fields for many cell types. Therefore, many potential biological functions can not be determined through screening at a large scale, and a focused screen with a carefully managed cell model is essential. This is important because it is likely that any given mutation or gene knockdown will eventually produce a phenotype or change in a signal transduction pathway. When such a change resulting from a mutation is identified, it may be tempting to conclude that the role for the mutation has been established, but it is only a role for the mutation in a cellular system, and may not be a role for the mutation in disease.
Concluding remarks
RNAi screening in a wide range of cellular systems to establish a disease mechanism is both subject to the technical concerns intrinsic to RNAi screening in general, such as off-target effects, as well as a strong link to biological relevance, because the observance of an effect in the model system does more than implicate a gene in a pathway, it is intended as evidence of an effect on disease. An example of this difference would be seen if a siRNA causes a change in assays in more than one system. If the disease area was diabetes, an effect could be observed in models for pancreatic beta-cells, skeletal muscle and the liver. An effect in all three systems would provide three models for studying the role of the gene in a biological context, but it may be only one of these systems that actually produces the effect in clinical diabetes. If the study looked at a genetic basis for an increased likelihood of cancer, effects in stromal, endothelial and inflammatory cells could similarly signify more contexts to study the gene than are relevant to the disease. While the characterisation of disease has been genuinely advanced through the application of recently developed methods for genetic analysis, determining the role of these mutations has also identified gaps in the linkage between many biological models used to develop therapeutics and the authentic mechanisms of human disease.
Acknowledgement
The SNP described in Figure 1 on page 40 makes use of data generated by the Wellcome Trust Case-Control Consortium. A full list of the investigators who contributed to the generation of the data is available from www.wtccc.org.uk. Funding for the project was provided by the Wellcome Trust under award 076113.
References
Boutros, M., and J. Ahringer. 2008. The art and design of genetic screens: RNA interference. Nature Reviews Genetics 9:554-566.
Birmingham, A., L. M. Selfors, T. Forster, D. Wrobel, C. J. Kennedy, E. Shanks, J. Santoyo-Lopez, D. J. Dunican, A. Long, D. Kelleher, Q. Smith, R. L. Beijersbergen, P. Ghazal, and C. E. Shamu. 2009. Statistical methods for analysis of high-throughput RNA interference screens. Nature Methods 6:569-575.
Echeverri, C. J., P. A. Beachy, B. Baum, M. Boutros, F. Buchholz, S. K. Chanda, J. Downward, J. Ellenberg, A. G. Fraser, N. Hacohen, W. C. Hahn, A. L. Jackson, A. Kiger, P. S. Linsley, L. Lum, Y. Ma, B. Mathey-Prevot, D. E. Root, D. M. Sabatini, J. Taipale, N. Perrimon, and R. Bernards. 2006. Minimizing the risk of reporting false positives in large-scale RNAi screens. Nature Methods 3:777-779.
Haney, S. A. 2007. Increasing the robustness and validity of RNAi screens. Pharmacogenomics 8:1037-1049.
Lum, P. Y., J. M. Derry, and E. E. Schadt. 2009. Integrative genomics and drug development. Pharmacogenomics 10:203-212.
Ng, S. B., E. H. Turner, P. D. Robertson, S. D. Flygare, A. W. Bigham, C. Lee, T. Shaffer, M. Wong, A. Bhattacharjee, E. E. Eichler, M. Bamshad, D. A. Nickerson, and J. Shendure. 2009. Targeted capture and massively parallel sequencing of 12 human exomes. Nature 461:272-276.
Lyssenko, V., A. Jonsson, P. Almgren, N. Pulizzi, B. Isomaa, T. Tuomi, G. Berglund, D. Altschuler, P. Nilson, and L. Groop. 2008. Clinical risk factors, DNA varients and the development of type 2 diabetes. New England Journal of Medicine 359:2220-2232.
Helgadottir, A., G. Thorleifsson, A. Manolescu, S. Gretarsdottir, T. Blondal, A. Jonasdottir, A. Jonasdottir, A. Sigurdsson, A. Baker, A. Palsson, G. Masson, D. F. Gudbjartsson, K. P. Magnusson, K. Andersen, L. A.I., V. M. Backman, S. Matthiasdottir, T. Jonsdottir, S. Palsson, H. Einarsdottir, S. Gunnarsdottir, A. Gylfason, V. Vaccarino, W. C. Hooper, M. P. Reilly, C. B. Granger, H. Austin, D. J. Rader, S. H. Shah, A. A. Quyyumi, J. R. Gulcher, G. Thorgeirsson, U. Thorsteinsdottir, A. Kong, and K. Stefansson. 2007. A common variant on chromosome 9p21 affects the risk of myocardial infarction. Science 316:1491-1493.
Liu, Y., H. K. Sanoff, H. Cho, C. E. Burd, C. Torrice, K. L. Mohlke, J. G. Ibrahim, N. E. Thomas, and N. E. Sharpless. 2009. INK4/ARF transcript expression is associated with chromosome 9p21 variants linked to atherosclerosis. PLoS One 4:e5027.
Echeverri, C. J., and N. Perrimon. 2006. High-throughput RNAi screening in cultured cells: a user’s guide. Nature Reviews Genetics 7:373-384.
Zhang, X. D. 2007. A pair on new statistical parameters for quality control in RNA interference high-throughput screening assays. Genomics 89:552-561.
Houlston, R. S., E. Webb, P. Broderick, A. M. Pittman, M. C. Di Bernardo, S. Lubbe, I. Chandler, J. Vijayakrishnan, K. Sullivan, S. Penegar, C. C. A. S. Consortium, L. Carvajal-Carmona, K. Howarth, E. Jaeger, S. L. Spain, A. Walther, E. Barclay, L. Martin, M. Gorman, E. Domingo, A. S. Teixeira, C. Consortium., D. Kerr, J. B. Cazier, I. Niittymäki, S. Tuupanen, A. Karhu, L. A. Aaltonen, I. P. Tomlinson, S. M. Farrington, A. Tenesa, J. G. Prendergast, R. A. Barnetson, R. Cetnarskyj, M. E. Porteous, P. D. Pharoah, T. Koessler, J. Hampe, S. Buch, C. Schafmayer, J. Tepel, S. Schreiber, H. Völzke, J. Chang-Claude, M. Hoffmeister, H. Brenner, B. W. Zanke, A. Montpetit, T. J. Hudson, S. Gallinger, I. C. C. G. A. Consortium, H. Campbell, and M. G. Dunlop. 2008. Meta-analysis of genome-wide association data identifies four new susceptibility loci for colorectal cancer. Nature Genetics 40:1426-1435.
Consortium, T. W. T. C. C. 2007. Genome-wide association study of 14,000 cases of seven common diseases and 3000 shared controls. Nature 447:661-678.
This website uses cookies to enable, optimise and analyse site operations, as well as to provide personalised content and allow you to connect to social media. By clicking "I agree" you consent to the use of cookies for non-essential functions and the related processing of personal data. You can adjust your cookie and associated data processing preferences at any time via our "Cookie Settings". Please view our Cookie Policy to learn more about the use of cookies on our website.
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorised as ”Necessary” are stored on your browser as they are as essential for the working of basic functionalities of the website. For our other types of cookies “Advertising & Targeting”, “Analytics” and “Performance”, these help us analyse and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these different types of cookies. But opting out of some of these cookies may have an effect on your browsing experience. You can adjust the available sliders to ‘Enabled’ or ‘Disabled’, then click ‘Save and Accept’. View our Cookie Policy page.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Cookie
Description
cookielawinfo-checkbox-advertising-targeting
The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Advertising & Targeting".
cookielawinfo-checkbox-analytics
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Analytics".
cookielawinfo-checkbox-necessary
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Performance".
PHPSESSID
This cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy
The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
zmember_logged
This session cookie is served by our membership/subscription system and controls whether you are able to see content which is only available to logged in users.
Performance cookies are includes cookies that deliver enhanced functionalities of the website, such as caching. These cookies do not store any personal information.
Cookie
Description
cf_ob_info
This cookie is set by Cloudflare content delivery network and, in conjunction with the cookie 'cf_use_ob', is used to determine whether it should continue serving “Always Online” until the cookie expires.
cf_use_ob
This cookie is set by Cloudflare content delivery network and is used to determine whether it should continue serving “Always Online” until the cookie expires.
free_subscription_only
This session cookie is served by our membership/subscription system and controls which types of content you are able to access.
ls_smartpush
This cookie is set by Litespeed Server and allows the server to store settings to help improve performance of the site.
one_signal_sdk_db
This cookie is set by OneSignal push notifications and is used for storing user preferences in connection with their notification permission status.
YSC
This cookie is set by Youtube and is used to track the views of embedded videos.
Analytics cookies collect information about your use of the content, and in combination with previously collected information, are used to measure, understand, and report on your usage of this website.
Cookie
Description
bcookie
This cookie is set by LinkedIn. The purpose of the cookie is to enable LinkedIn functionalities on the page.
GPS
This cookie is set by YouTube and registers a unique ID for tracking users based on their geographical location
lang
This cookie is set by LinkedIn and is used to store the language preferences of a user to serve up content in that stored language the next time user visit the website.
lidc
This cookie is set by LinkedIn and used for routing.
lissc
This cookie is set by LinkedIn share Buttons and ad tags.
vuid
We embed videos from our official Vimeo channel. When you press play, Vimeo will drop third party cookies to enable the video to play and to see how long a viewer has watched the video. This cookie does not track individuals.
wow.anonymousId
This cookie is set by Spotler and tracks an anonymous visitor ID.
wow.schedule
This cookie is set by Spotler and enables it to track the Load Balance Session Queue.
wow.session
This cookie is set by Spotler to track the Internet Information Services (IIS) session state.
wow.utmvalues
This cookie is set by Spotler and stores the UTM values for the session. UTM values are specific text strings that are appended to URLs that allow Communigator to track the URLs and the UTM values when they get clicked on.
_ga
This cookie is set by Google Analytics and is used to calculate visitor, session, campaign data and keep track of site usage for the site's analytics report. It stores information anonymously and assign a randomly generated number to identify unique visitors.
_gat
This cookies is set by Google Universal Analytics to throttle the request rate to limit the collection of data on high traffic sites.
_gid
This cookie is set by Google Analytics and is used to store information of how visitors use a website and helps in creating an analytics report of how the website is doing. The data collected including the number visitors, the source where they have come from, and the pages visited in an anonymous form.
Advertising and targeting cookies help us provide our visitors with relevant ads and marketing campaigns.
Cookie
Description
advanced_ads_browser_width
This cookie is set by Advanced Ads and measures the browser width.
advanced_ads_page_impressions
This cookie is set by Advanced Ads and measures the number of previous page impressions.
advanced_ads_pro_server_info
This cookie is set by Advanced Ads and sets geo-location, user role and user capabilities. It is used by cache busting in Advanced Ads Pro when the appropriate visitor conditions are used.
advanced_ads_pro_visitor_referrer
This cookie is set by Advanced Ads and sets the referrer URL.
bscookie
This cookie is a browser ID cookie set by LinkedIn share Buttons and ad tags.
IDE
This cookie is set by Google DoubleClick and stores information about how the user uses the website and any other advertisement before visiting the website. This is used to present users with ads that are relevant to them according to the user profile.
li_sugr
This cookie is set by LinkedIn and is used for tracking.
UserMatchHistory
This cookie is set by Linkedin and is used to track visitors on multiple websites, in order to present relevant advertisement based on the visitor's preferences.
VISITOR_INFO1_LIVE
This cookie is set by YouTube. Used to track the information of the embedded YouTube videos on a website.